Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy

Area of Science:

• Oncology
• Nanomedicine
• Drug Delivery

Background:

• Drug resistance, both intrinsic and acquired, is a primary reason for chemotherapy failure in cancer patients.
• Multi drug resistance (MDR) involves tumor cells becoming cross-resistant to various anticancer drugs.
• Nanovector-mediated drug delivery presents an innovative strategy to overcome MDR.

Purpose of the Study:

• To review nanovectors designed for efficient drug delivery in overcoming multi drug resistance (MDR).
• To discuss the mechanisms of action for nanovector-based strategies against MDR.
• To explore future opportunities in nanodevices for MDR circumvention.

Main Methods:

• Review of nanovectors including polymer-drug conjugates, polymeric micelles, nanotubes, LbL nanocapsules, and silica and gold nanoparticles.
• Analysis of nanovector systems designed for delivering anthracyclines, vinca alkaloids, and taxanes.
• Discussion of nanovector development for specific MDR targeting and multi-cargo delivery.

Main Results:

• Various nanovectors show potential for delivering anticancer drugs and overcoming MDR.
• Nanovector design and mechanisms of action are crucial for effective MDR circumvention.
• Nanoparticle-based systems offer targeted delivery and enhanced therapeutic efficacy.

Conclusions:

• Nanovector-mediated drug delivery is a promising approach to overcome multi drug resistance (MDR) in cancer.
• Further development of nanodevices is essential for advancing nanochemotherapy against MDR.
• Designing nanovectors for multi-cargo delivery holds significant potential for future cancer treatments.